Watson is committed to expanding its Global Generic and Global Brands product portfolios and to bringing to market value-added products that benefit consumers. We devote significant resources to the research and development (R&D) of generic and proprietary products.

Watson’s research and development activities capitalize on the Company’s expertise in numerous drug delivery technologies, including solid dosage form, oral controlled and sustained release, transdermal, and oral transmucosal technologies. Watson seeks to complement internal development activities with strategic alliances, mergers and acquisitions, and select product and technology acquisitions as appropriate.